KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Short term Debt: 2020-2024

Historic Short term Debt for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $8.1 million.

  • AbCellera Biologics' Short term Debt fell 82.95% to $8.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.8 million, marking a year-over-year decrease of 82.95%. This contributed to the annual value of $8.1 million for FY2024, which is 83.98% down from last year.
  • AbCellera Biologics' Short term Debt amounted to $8.1 million in FY2024, which was down 83.98% from $50.5 million recorded in FY2023.
  • AbCellera Biologics' 5-year Short term Debt high stood at $50.5 million for FY2023, and its period low was $8.1 million during FY2024.
  • Moreover, its 3-year median value for Short term Debt was $44.2 million (2022), whereas its average is $34.3 million.
  • Per our database at Business Quant, AbCellera Biologics' Short term Debt soared by 92.77% in 2022 and then crashed by 83.98% in 2024.
  • AbCellera Biologics' Short term Debt (Yearly) stood at $13.4 million in 2020, then surged by 71.01% to $22.9 million in 2021, then skyrocketed by 92.77% to $44.2 million in 2022, then rose by 14.17% to $50.5 million in 2023, then plummeted by 83.98% to $8.1 million in 2024.